Mayor Tommy Battle joined community and industry leaders to celebrate the groundbreaking of Glaukos Corporation’s new research and manufacturing campus in Cummings Research Park. The global ophthalmic pharmaceutical and medical technology company specializes in therapies for glaucoma, corneal disorders, and retinal diseases.
Huntsville’s Innovation Ecosystem
Mayor Battle highlighted Huntsville’s longstanding investment in science and advanced manufacturing, noting that Glaukos’ expansion showcases the city’s ability to attract companies shaping the future of human health.
Why Huntsville Was Chosen
Glaukos Chairman and CEO Thomas Burns said the company evaluated more than 100 sites worldwide before selecting Huntsville. He cited the region’s strong talent pool and supportive business climate as key factors.
Economic Impact
The project represents an $82 million capital investment and is expected to create 154 full-time jobs by 2030 under a city-backed economic development agreement.
Sign up for the Homely Huntsville newsletter to stay up to date on Huntsville.
